GO:0019981 interleukin-6 binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019981 (interleukin-6 binding) is a molecular function defined as binding to interleukin-6 (IL-6), a pleiotropic cytokine.
• IL-6 binding is the first step in IL-6 signaling, which involves the IL-6 receptor (IL-6R) and glycoprotein 130 (gp130).
• IL-6 binding proteins include the membrane-bound IL-6R (CD126) and soluble IL-6R (sIL-6R), enabling classic and trans-signaling.
• Dysregulated IL-6 binding and signaling are implicated in inflammatory diseases, COVID-19 severity, and cancer.
• IL-6 binding is regulated by proteolytic shedding of IL-6R and by expression of negative regulators like SOCS proteins.
• CRISPR-based models (knockout, knock-in, point mutation) are essential to dissect the causal roles of IL-6 binding in disease.
Description
Interleukin-6 (IL-6) is a master cytokine that regulates immune responses, hematopoiesis, and tissue regeneration. The molecular function GO:0019981, interleukin-6 binding, describes the selective interaction of a protein with IL-6. This binding event is the initial and essential step for IL-6 signal transduction, which can occur via membrane-bound IL-6 receptor (IL-6R) or soluble IL-6R (sIL-6R). Understanding IL-6 binding is critical because it determines the specificity and magnitude of downstream signaling, influencing outcomes in infection, inflammation, and cancer. Researchers study IL-6 binding to elucidate how cytokines orchestrate immune responses and to identify therapeutic targets. For example, genetic variants that alter IL-6 binding or expression can affect susceptibility to severe COVID-19. Moreover, IL-6 binding to its receptor is a target for monoclonal antibodies like tocilizumab, underscoring its clinical relevance. Thus, GO:0019981 represents a focal point for both basic and translational research. This article provides a comprehensive overview of IL-6 binding, covering its definition, mechanism, key genes, disease associations, and experimental methods, with a focus on CRISPR-based approaches for functional validation.
interleukin-6 binding At A Glance
| GO ID | GO:0019981 |
|---|---|
| GO term | interleukin-6 binding |
| Ontology | molecular_function |
| Synonym | IL-6 binding |
| Major function | Binding to interleukin-6, initiating signal transduction |
| Major proteins | IL-6R (CD126), gp130 (IL6ST), soluble IL-6R |
| Associated processes | JAK/STAT signaling, acute phase response, immune regulation |
| Disease relevance | Inflammation, COVID-19, cancer, autoimmune diseases |
What Is GO:0019981?
Interleukin-6 binding (GO:0019981) is the molecular function of selectively interacting with interleukin-6, a cytokine. This binding is non-covalent and reversible, and it is typically mediated by specific domains in receptors such as IL-6R or other IL-6-binding proteins. The function is essential for initiating signaling cascades that regulate cell growth, differentiation, and survival.
Why Is interleukin-6 binding Important in Cell Biology?
IL-6 binding is a central node in the cytokine network, controlling the initiation of signaling pathways that affect virtually every organ system. Dysregulation of IL-6 binding contributes to chronic inflammation, cytokine storms, and tumor progression. Therefore, understanding the molecular details of IL-6 binding is crucial for developing targeted therapies and for interpreting genetic variants that affect disease susceptibility.
• IL-6 binding initiates JAK/STAT signaling, which is critical for immune cell differentiation and acute phase response.
• Soluble IL-6R generated by proteolytic cleavage enables trans-signaling in cells lacking membrane-bound IL-6R, expanding IL-6 targets.
• IL-6 binding is implicated in the pathogenesis of severe COVID-19, where elevated IL-6 levels correlate with poor prognosis.
• Genetic variants disrupting IL-6 binding or expression can protect against severe COVID-19.
• IL-6 binding to its receptor is a therapeutic target in rheumatoid arthritis and other inflammatory diseases.
• In cancer, IL-6 binding promotes tumor growth and survival through autocrine and paracrine loops.
• IL-6 binding regulates liver regeneration and fibrosis, as shown in NAFLD models.
• Proteolytic control of IL-6 binding by shedding enzymes modulates signaling amplitude.
• IL-6 binding is essential for B cell maturation and antibody production.
• Studying IL-6 binding helps identify biomarkers for sepsis and respiratory failure.
What Happens During interleukin-6 binding?
IL-6 Recognition and Receptor Engagement
In simple terms: IL-6 binds to its receptor like a key in a lock.
IL-6 binding begins with the specific recognition of IL-6 by the IL-6 receptor (IL-6R). The interaction involves the cytokine's four-helix bundle and the receptor's cytokine-binding homology region. This binding is highly specific and is the first step in signal transduction.
Formation of the Signaling Complex
In simple terms: The IL-6/IL-6R complex recruits another protein to start signaling.
After IL-6 binds to IL-6R, the complex recruits glycoprotein 130 (gp130), leading to the formation of a hexameric signaling complex. This assembly triggers activation of associated JAK kinases, which phosphorylate gp130 and initiate downstream cascades.
Classic vs. Trans-Signaling
In simple terms: IL-6 can signal in cells with or without its receptor.
Classic signaling occurs when IL-6 binds to membrane-bound IL-6R on target cells. Alternatively, IL-6 can bind to soluble IL-6R (sIL-6R) to form a complex that can stimulate cells lacking membrane IL-6R, a process called trans-signaling. This expands the range of IL-6-responsive cells.
Downstream Signaling Activation
In simple terms: Binding triggers a chain reaction inside the cell.
The IL-6/IL-6R/gp130 complex activates JAK/STAT, MAPK, and PI3K pathways. Specifically, JAK-mediated phosphorylation of STAT3 leads to its dimerization and nuclear translocation, where it regulates gene expression.
Regulation by Proteolysis
In simple terms: Enzymes can cut the receptor to control signaling.
Proteolytic shedding of IL-6R by metalloproteases such as ADAM17 generates sIL-6R, which modulates IL-6 binding and signaling. This process is tightly regulated and affects the balance between classic and trans-signaling.
Key Genes Involved in GO:0019981 interleukin-6 binding
The following genes encode proteins that directly bind IL-6 or are essential for IL-6 binding and signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL6 | Encodes interleukin-6 cytokine | Central to inflammation and immune response; target for knockout and knock-in models |
| IL6R | Encodes IL-6 receptor alpha chain (CD126) | Mediates IL-6 binding; mutations affect signaling and disease |
| IL6ST | Encodes gp130, signal-transducing subunit | Required for IL-6 signaling; knockout is embryonic lethal |
| JAK1 | Janus kinase 1 | Phosphorylates gp130 upon IL-6 binding; essential for signaling |
| JAK2 | Janus kinase 2 | Alternative JAK for IL-6 signaling; involved in hematopoiesis |
| STAT3 | Signal transducer and activator of transcription 3 | Key downstream effector; regulates gene expression |
| SOCS1 | Suppressor of cytokine signaling 1 | Negative regulator of IL-6 signaling; feedback inhibition |
| SOCS3 | Suppressor of cytokine signaling 3 | Inhibits JAK activity; regulates IL-6 responses |
| ADAM17 | Metalloprotease that sheds IL-6R | Generates soluble IL-6R; modulates trans-signaling |
| ADAM10 | Metalloprotease with sheddase activity | Contributes to IL-6R shedding |
| CTCF | Chromatin insulator protein | Regulates IL6 expression; variants affect COVID-19 severity |
| CRP | C-reactive protein | Acute phase protein induced by IL-6; biomarker |
| MIR223 | MicroRNA-223 | Regulated by IL-6 signaling; involved in NAFLD fibrosis |
| IL11 | Interleukin-11 | Related cytokine with similar signaling; proteolytic control |
| IL6R (soluble) | Soluble form of IL-6R | Enables trans-signaling; therapeutic target |
| GP130 (soluble) | Soluble gp130 | Inhibits IL-6 trans-signaling by binding sIL-6R |
| TNF | Tumor necrosis factor | Cytokine that can synergize with IL-6; inflammation |
| IL1B | Interleukin-1 beta | Pro-inflammatory cytokine; often co-regulated with IL-6 |
How Is interleukin-6 binding Regulated?
IL-6 binding and signaling are regulated at multiple levels. Proteolytic shedding of IL-6R by ADAM17 and ADAM10 controls the availability of soluble receptor and thus trans-signaling. Negative feedback loops involve SOCS proteins, which are induced by IL-6 and inhibit JAK activity. Additionally, genetic variants in the IL6 promoter or enhancer regions can affect IL-6 production and binding. The balance between classic and trans-signaling is further modulated by soluble gp130, which acts as a decoy.
interleukin-6 binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL6 | Severe COVID-19, cytokine storm | IL6 knockout mice or human iPSC-derived macrophages |
| IL6R | Rheumatoid arthritis, inflammation | IL6R knockout or point mutation knock-in mice |
| STAT3 | Cancer, autoimmune diseases | STAT3 knockout or conditional knock-in models |
| ADAM17 | Inflammatory diseases, shedding defects | ADAM17 knockout or catalytic-dead knock-in |
| SOCS3 | Inflammation, insulin resistance | SOCS3 knockout mice |
IL-6 binding in COVID-19 and sepsis
Elevated IL-6 levels and increased IL-6 binding are associated with severe COVID-19 and sepsis. High IL-6 binding to its receptor amplifies inflammatory signaling, leading to cytokine storms and respiratory failure. A low-producing haplotype of IL-6 that disrupts CTCF binding is protective against severe COVID-19, highlighting the importance of IL-6 regulation.
IL-6 binding in cancer and chronic inflammation
IL-6 binding promotes tumor cell proliferation, survival, and angiogenesis through autocrine and paracrine loops. In cancers such as multiple myeloma and hepatocellular carcinoma, elevated IL-6 binding and STAT3 activation are common. Targeting IL-6 binding with monoclonal antibodies (e.g., tocilizumab) is a therapeutic strategy.
IL-6 binding in liver disease
IL-6 binding and signaling play a dual role in liver disease. In NAFLD, myeloid-specific IL-6 signaling promotes microRNA-223-enriched exosome production, which attenuates fibrosis. Conversely, excessive IL-6 trans-signaling can exacerbate inflammation and fibrosis.
From interleukin-6 binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IL-6 binding affect immune response? | IL6 or IL6R knockout mice |
| How do point mutations in IL6R affect binding affinity? | IL6R point-mutation knock-in mice or cell lines |
| What is the effect of soluble IL-6R overexpression? | Transgenic mice overexpressing soluble IL6R |
| Can tagged IL-6R track receptor dynamics? | Knock-in of fluorescently tagged IL6R |
| Does a disease-associated variant alter IL-6 binding? | CRISPR knock-in of the variant in cell lines |
| What genes are essential for IL-6 signaling? | Genome-wide CRISPR knockout library screening |
How to Study the interleukin-6 binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | Characterizing IL-6/IL-6R interaction |
| Molecular dynamics | Atomic-level interactions | Modeling binding interface |
| CRISPR knockout screening | Gene essentiality for IL-6 binding | Identifying novel regulators |
| Flow cytometry | Cell surface IL-6R expression | Immune cell phenotyping |
| ELISA | Soluble IL-6 and sIL-6R levels | Clinical biomarker studies |
| Western blot | JAK/STAT activation | Signaling pathway analysis |
| Co-immunoprecipitation | Protein-protein interactions | Detecting IL-6/IL-6R complexes |
| RNA-seq | Transcriptional changes | Downstream gene expression profiling |
Surface plasmon resonance (SPR) for binding affinity
SPR measures real-time binding kinetics between IL-6 and its receptor. It provides quantitative data on association and dissociation rates, which are critical for understanding the strength of IL-6 binding.
Molecular dynamics simulations
Computational simulations can model the interaction between IL-6 and IL-6R at atomic resolution, revealing key residues and conformational changes that occur upon binding.
CRISPR screening for regulators of IL-6 binding
Genome-wide CRISPR knockout or activation screens can identify genes that regulate IL-6 binding and signaling. These screens are powerful for discovering novel components of the pathway.
Flow cytometry and immunoassays
Flow cytometry can detect cell surface IL-6R expression, while ELISA and other immunoassays quantify soluble IL-6 and sIL-6R levels in biological samples.
How CRISPR Can Be Used to Study GO:0019981 interleukin-6 binding
Knockout
CRISPR knockout of IL6, IL6R, or IL6ST can completely abolish IL-6 binding and signaling, providing a clean background to study downstream effects. These models are valuable for validating drug targets and understanding disease mechanisms.
Point Mutation
Introducing specific point mutations in IL6R or IL6 can alter binding affinity or specificity. For example, mutations identified in patients can be recapitulated to assess their impact on IL-6 binding and signaling.
Knock-in
Knock-in of tagged IL-6R (e.g., fluorescent or epitope tags) allows real-time tracking of receptor localization and dynamics. Knock-in of disease-associated variants helps determine causality.
Overexpression
Overexpression of IL-6 or soluble IL-6R using CRISPR activation or lentiviral vectors can mimic pathological states such as cytokine storms. These models are useful for testing inhibitors of IL-6 binding.
How EDITGENE Supports interleukin-6 binding Research
Researchers studying interleukin-6 binding-related genes often need to determine whether a candidate gene is causally involved in a specific disease or pathway. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for interleukin-6 binding research.
Frequently Asked Questions About interleukin-6 binding
What is interleukin-6 binding?
Interleukin-6 binding (GO:0019981) is the molecular function of selectively interacting with interleukin-6, a cytokine involved in immune and inflammatory responses.
What genes are involved in interleukin-6 binding?
Key genes include IL6 (encoding IL-6), IL6R (IL-6 receptor), and IL6ST (gp130), as well as downstream signaling molecules like JAK1, JAK2, and STAT3.
How does interleukin-6 binding initiate signaling?
IL-6 binding to IL-6R induces formation of a complex with gp130, activating JAK kinases and downstream STAT3 signaling.
What diseases are associated with interleukin-6 binding?
Dysregulated IL-6 binding is linked to severe COVID-19, sepsis, rheumatoid arthritis, and various cancers.
What is the difference between classic and trans-signaling of IL-6?
Classic signaling uses membrane-bound IL-6R, while trans-signaling involves soluble IL-6R that can activate cells lacking membrane IL-6R.
How is interleukin-6 binding regulated?
It is regulated by proteolytic shedding of IL-6R, expression of SOCS proteins, and genetic variants affecting IL6 expression.
What methods are used to study interleukin-6 binding?
Common methods include surface plasmon resonance, molecular dynamics simulations, CRISPR screening, and flow cytometry.
Can CRISPR be used to study interleukin-6 binding?
Yes, CRISPR knockout, knock-in, and point mutation models are powerful tools to dissect the role of IL-6 binding in health and disease.
What is the role of soluble IL-6R in IL-6 binding?
Soluble IL-6R binds IL-6 and enables trans-signaling, expanding the range of cells responsive to IL-6.
Why is interleukin-6 binding important for COVID-19?
Elevated IL-6 binding and signaling contribute to cytokine storms and severe outcomes in COVID-19 patients.
Conclusion
Interleukin-6 binding (GO:0019981) is a fundamental molecular function that initiates a cascade of signaling events critical for immunity, inflammation, and tissue homeostasis. Its dysregulation is implicated in a wide range of diseases, from COVID-19 to cancer. Understanding the precise mechanisms of IL-6 binding, including the roles of IL-6R, gp130, and soluble forms, is essential for developing targeted therapies. CRISPR-based models offer unparalleled opportunities to dissect these mechanisms and validate therapeutic targets.
References
- 1. Uciechowski P et al.. 2020. Interleukin-6: A Masterplayer in the Cytokine Network.. Oncology 98(3):131-137 PMID: 31958792
- 2. Tanaka T et al.. 2016. Regulation of IL-6 in Immunity and Diseases.. Adv Exp Med Biol 941:79-88 PMID: 27734409
- 3. Wei Z et al.. 2025. The accuracy of heparin-binding protein and interleukin-6 in predicting prognosis of severe pneumonia with sepsis patients.. Front Cell Infect Microbiol 15:1554214 PMID: 41293058
- 4. Chen T et al.. 2021. A Low-Producing Haplotype of Interleukin-6 Disrupting CTCF Binding Is Protective against Severe COVID-19.. mBio 12(5):e0137221 PMID: 34634929
- 5. Hou X et al.. 2021. Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.. Hepatology 74(1):116-132 PMID: 33236445
- 6. Saridaki M et al.. 2021. Integration of heparin-binding protein and interleukin-6 in the early prediction of respiratory failure and mortality in pneumonia by SARS-CoV-2 (COVID-19).. Eur J Clin Microbiol Infect Dis 40(7):1405-1412 PMID: 33515095
- 7. Gupta M et al.. 2021. Molecular dynamics analysis of the binding of human interleukin-6 with interleukin-6 α-receptor.. Proteins 89(2):163-173 PMID: 32881084
- 8. Lokau J et al.. 2017. Proteolytic control of Interleukin-11 and Interleukin-6 biology.. Biochim Biophys Acta Mol Cell Res 1864(11 Pt B):2105-2117 PMID: 28630024
